不稳定型心绞痛低分子肝素治疗的远期预后

Impact of long-term prognosis of low-molecular-weight heparin in unstable angina

目的 探讨低分子肝素治疗对不稳定型心绞痛远期预后的影响。方法 对2000年2月～2001年12月诊断为不稳定型心绞痛并使用低分子肝素治疗和常规药物治疗的病人进行追踪随访。结果 肝素治疗组41例，随访时间2，0，3．8（平均2．9±1.7）年；常规治疗组49例，随访时间2．0—4．1（平均2．8±1．4）年；两组随访时间无显著性差异（P〉0．05）。两组患者随访期内的心绞痛复发、心肌梗死、心功能不全加重、心脏死亡事件、非心脏死亡事件的发生率均无统计学差异（P〉0．05）。结论 低分子肝素治疗并不能减少不稳定型心绞痛患者远期临床事件的发生，其远期疗效与常规药物治疗相似。

Objective To study long-term prognosis of low-molecular-weight heparin in unstable angina. Methods We followed up the patients who was diagnosed as unstable angina and admitted to our hospital during Feb. 2000 to Dee. 2001. In the hospital, they were treated with low-molecular heparin or routine medicine without low-molecular heparin. Results 41 cases in heparin group and 49 cases in routine medicine group was followed up in 2.0 to 4. 1 years after discharge. There were no significant difference between two groups during floow-up survey in angina recurrence, acute myocardiae infarction, aggravation of heart failure, cardiac death and non-cardiac death （ P 〉 0.05 ）, Conclusion Long-term prognosis of low-molecular-weight heparin in unstable angina is not better than that of routine medicine.